BUZZ-C4 <a href="https://laohu8.com/S/LENZ">Therapeutics</a> climbs after partnership with Pfizer for cancer therapy trial** Shares of drug developer C4 Therapeutics CCCC.O rise 8% to $2.40 premarket
** Co says it has partnered with Pfizer PFE.N to test a combination therapy for cancer
** CCCC will test its drug cemsidomide with Pfizer's elranatamab in patients with multiple myeloma, a type of blood cancer, who have already received at least one prior treatment
** Under the deal, Pfizer will supply elranatamab, sold under the brand name Elrexfio, at no cost, while C4 Therapeutics will lead and sponsor the early-stage trial, which is expected to begin in Q2 of 2026
** As of last close, stock down 38% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.